Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells.

Yang C, Zhang JJ, Peng YP, Zhu Y, Yin LD, Wei JS, Gao WT, Jiang KR, Miao Y.

J Transl Med. 2017 Oct 19;15(1):211. doi: 10.1186/s12967-017-1308-3.

2.

Paired Expression Analysis of Tumor Cell Surface Antigens.

Orentas RJ, Sindiri S, Duris C, Wen X, He J, Wei JS, Jarzembowski J, Khan J.

Front Oncol. 2017 Aug 21;7:173. doi: 10.3389/fonc.2017.00173. eCollection 2017.

3.

Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis.

Peng YP, Zhu XL, Yin LD, Zhu Y, Wei JS, Wu JL, Miao Y.

Sci Rep. 2017 Mar 15;7(1):185. doi: 10.1038/s41598-017-00311-8.

4.

Revealing homogeneous plastic deformation in dendrite-reinforced Ti-based metallic glass composites under tension.

Wu FF, Wei JS, Chan KC, Chen SH, Zhao RD, Zhang GA, Wu XF.

Sci Rep. 2017 Feb 14;7:42598. doi: 10.1038/srep42598.

5.

PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer.

Peng YP, Zhu Y, Yin LD, Zhang JJ, Wei JS, Liu X, Liu XC, Gao WT, Jiang KR, Miao Y.

J Exp Clin Cancer Res. 2017 Feb 13;36(1):30. doi: 10.1186/s13046-017-0500-x.

6.

Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma.

Brohl AS, Patidar R, Turner CE, Wen X, Song YK, Wei JS, Calzone KA, Khan J.

Genet Med. 2017 Aug;19(8):955-958. doi: 10.1038/gim.2016.206. Epub 2017 Jan 26.

7.

The Expression and Prognostic Roles of MCMs in Pancreatic Cancer.

Peng YP, Zhu Y, Yin LD, Zhang JJ, Guo S, Fu Y, Miao Y, Wei JS.

PLoS One. 2016 Oct 3;11(10):e0164150. doi: 10.1371/journal.pone.0164150. eCollection 2016.

8.

Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.

Peng YP, Xi CH, Zhu Y, Yin LD, Wei JS, Zhang JJ, Liu XC, Guo S, Fu Y, Miao Y.

Oncotarget. 2016 Oct 11;7(41):66586-66594. doi: 10.18632/oncotarget.11953.

9.

MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.

Chang W, Brohl AS, Patidar R, Sindiri S, Shern JF, Wei JS, Song YK, Yohe ME, Gryder B, Zhang S, Calzone KA, Shivaprasad N, Wen X, Badgett TC, Miettinen M, Hartman KR, League-Pascual JC, Trahair TN, Widemann BC, Merchant MS, Kaplan RN, Lin JC, Khan J.

Clin Cancer Res. 2016 Aug 1;22(15):3810-20. doi: 10.1158/1078-0432.CCR-15-2717. Epub 2016 Mar 18.

10.

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J.

Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10.

11.

Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.

Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, McDaniel LD, Diamond M, Hart LS, Zhu S, Durbin AD, Abraham BJ, Anders L, Tian L, Zhang S, Wei JS, Khan J, Bramlett K, Rahman N, Capasso M, Iolascon A, Gerhard DS, Guidry Auvil JM, Young RA, Hakonarson H, Diskin SJ, Look AT, Maris JM.

Nature. 2015 Dec 17;528(7582):418-21. doi: 10.1038/nature15540. Epub 2015 Nov 11.

12.

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.

Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J.

Oncotarget. 2015 Nov 3;6(34):35247-62. doi: 10.18632/oncotarget.6208.

13.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-NĂ© P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

14.

CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus.

Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei JS, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, Diskin SJ, Maris JM, Cole KA.

Cancer Res. 2015 Aug 1;75(15):3155-66. doi: 10.1158/0008-5472.CAN-14-3613. Epub 2015 Jun 22.

15.

Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma.

Ji J, Zheng X, Forgues M, Yamashita T, Wauthier EL, Reid LM, Wen X, Song Y, Wei JS, Khan J, Thorgeirsson SS, Wang XW.

Hepatology. 2015 Sep;62(3):829-40. doi: 10.1002/hep.27886. Epub 2015 Jun 30.

16.

Clonality and evolutionary history of rhabdomyosarcoma.

Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, Khan J.

PLoS Genet. 2015 Mar 13;11(3):e1005075. doi: 10.1371/journal.pgen.1005075. eCollection 2015 Mar.

17.

Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan Q, Weiss WA.

Cell Rep. 2014 Nov 6;9(3):1034-46. doi: 10.1016/j.celrep.2014.09.046. Epub 2014 Oct 23.

18.

Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction.

Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, Miao Y, Zhu Y.

BMC Cancer. 2014 Oct 2;14:738. doi: 10.1186/1471-2407-14-738.

19.

The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.

Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J.

PLoS Genet. 2014 Jul 10;10(7):e1004475. doi: 10.1371/journal.pgen.1004475. eCollection 2014 Jul. Erratum in: PLoS Genet. 2014 Aug;10(8):e1004629.

20.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.

Cancer Discov. 2014 Feb;4(2):216-31. doi: 10.1158/2159-8290.CD-13-0639. Epub 2014 Jan 23.

Supplemental Content

Loading ...
Support Center